Abstract
Subclinical antibody-mediated rejection is defined as the presence of circulating donor HLA specific antibodies with the presence of typical pathological finding of antibody-mediated rejection and no change in graft function. It is known to be associated with poor outcome. Bortezomib is a proteasome inhibitor which has been used recently in treatment of antibody mediated rejection with varying degrees of success. It acts on antibodies producing plasma cells. It is commonly used with intravenous immunoglobulin infusion, therapeutic plasma exchange and rituximab and prednisone.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
